Prediction of Cardiovascular Risk Factors in Patients With Obesity Using QRISK3 Score
Author(s)
Bhavesh Dharmani, PharmD1, Sarita Jangra, M.Pharm, PhD2.
1Student, Chitkara University, Rajpura, India, 2Department of Pharmacy Practice, Chitkara College of Pharmacy, Chitkara University, Punjab, India (140401), Rajpura, India.
1Student, Chitkara University, Rajpura, India, 2Department of Pharmacy Practice, Chitkara College of Pharmacy, Chitkara University, Punjab, India (140401), Rajpura, India.
OBJECTIVES: This open label prospective study is aimed to understand relationship between Body Mass Index and Waist Hip Ratio with predictive biomarkers Afamin and Adropin for cardiovascular disease integrating with QRISK3 score in obese patients. Cardiovascular disease is the leading cause of death worldwide; therefore, predicting future risk of cardiovascular disease is an important tool for disease prevention.
METHODS: 100 patients were recruited for this study and divided in 2 groups: Group A (obese patients) and Group B (non-obese patients). Anthropometric measurements, biochemical and Biomarker analysis were performed with QRISK3 assessment to predict cardiovascular risk.
RESULTS: The mean Body Mass Index and Waist Hip Ratio of Group A were significantly different from Group B, with a mean Body Mass Index score of (34.18±0.47) in Group A compared to (24.80±0.45) in Group B, and mean Waist Hip Ratio score of (1.01±0.02, 0.73±0.01) in both groups, respectively. Afamin levels for Group A were elevated and were concluded to be (155.31±2.19) whereas the Group B levels showed (72.53±2.09) (t = 25.5, p value <0.0001, 95%, CI= -82.41,-70.51). And Adropin levels were concluded as (3.32±0.07) for Group B and they were reduced in Group A (1.98±0.10) (t=1.183, p value <0.0001, 95%, CI=-82.41,-70.51). The mean estimated risk score with QRISK3 in Group A (11.45±1.07) and Group B (5.15±0.79) were statistically significant different with p-value <0.0001. QRISK3 predicted that 58% cases in mild and moderate risk category in Group A and 22% in Group B. In Group A, QRISK3, 10% cases were in higher risk category while Group B it was12%.
CONCLUSIONS: Obese patients are at higher risk to develop cardiovascular diseases according to QRISK3 assessment. The biomarker Afamin was found increased in obese patients with a positive correlation with Body Mass Index and Waist Hip Ratio whereas Adropin was seen reduced in Group A as compared to Group B.
METHODS: 100 patients were recruited for this study and divided in 2 groups: Group A (obese patients) and Group B (non-obese patients). Anthropometric measurements, biochemical and Biomarker analysis were performed with QRISK3 assessment to predict cardiovascular risk.
RESULTS: The mean Body Mass Index and Waist Hip Ratio of Group A were significantly different from Group B, with a mean Body Mass Index score of (34.18±0.47) in Group A compared to (24.80±0.45) in Group B, and mean Waist Hip Ratio score of (1.01±0.02, 0.73±0.01) in both groups, respectively. Afamin levels for Group A were elevated and were concluded to be (155.31±2.19) whereas the Group B levels showed (72.53±2.09) (t = 25.5, p value <0.0001, 95%, CI= -82.41,-70.51). And Adropin levels were concluded as (3.32±0.07) for Group B and they were reduced in Group A (1.98±0.10) (t=1.183, p value <0.0001, 95%, CI=-82.41,-70.51). The mean estimated risk score with QRISK3 in Group A (11.45±1.07) and Group B (5.15±0.79) were statistically significant different with p-value <0.0001. QRISK3 predicted that 58% cases in mild and moderate risk category in Group A and 22% in Group B. In Group A, QRISK3, 10% cases were in higher risk category while Group B it was12%.
CONCLUSIONS: Obese patients are at higher risk to develop cardiovascular diseases according to QRISK3 assessment. The biomarker Afamin was found increased in obese patients with a positive correlation with Body Mass Index and Waist Hip Ratio whereas Adropin was seen reduced in Group A as compared to Group B.
Conference/Value in Health Info
2025-09, ISPOR Real-World Evidence Summit 2025, Tokyo, Japan
Value in Health Regional, Volume 49S (September 2025)
Code
RWD29
Topic Subcategory
Distributed Data & Research Networks
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory)